OCTOBER 2024LIFE SCIENCES REVIEW 19process focuses on projects that directly benefit patients, often foregoing immediate financial gains. This patient-centric approach leads the company to go above and beyond standard practices.For instance, when a patient in Sicily urgently needed medication on a Saturday morning, BIOVIIIx covered the costs to ensure its timely delivery. During the COVID-19 pandemic, a young patient from Liguria was stranded in the Canary Islands. His mother contacted a clinician, who then reached out to BIOVIIIx. The company promptly organised a special delivery, providing the necessary treatment at no cost.These compassionate acts reassure patients of the company's genuine commitment to their well-being. This ethical approach has also resulted in successful business outcomes, with BIOVIIIx achieving double-digit growth each year."We are seeking reliable solutions for haemophilia patients, addressing not only their physical but their emotional concerns as well," explains Rosiello. Recognising the importance of psychological support, BIOVIIIx launched initiatives to provide specialised psychologists for families affected by haemophilia. These programs, introduced to haemophilia associations, help families better accept and manage their condition, teaching them how to live as normally as possible. The commitment to these principles has contributed to its growth and success, reinforcing the belief that good human activities lead to positive business outcomes.In addition, oral hygiene challenges faced by haemophilia patients are also addressed. By collaborating with key opinion leaders, the company has developed educational programs to train dentists on the specific needs of these patients. Starting in Italy and expanding to Germany, this initiative ensures healthcare providers are well-equipped to manage haemophilia patients and help them navigate the complexities of their condition.Its patient-centric approach, despite logistical challenges, is a distinguishing feature. It ensures that even patients in remote areas receive the necessary care. This philosophy has earned it respect and recognition, demonstrating its commitment to improving patients' lives.Advancing Care in Treatment and Patient Advocacy A great milestone for this family-run company is the acquisition of Hematris GmbH, a German company that owns the Hematrix active patch. This patch is a lifesaver for haemophilia patients struggling with excessive blood loss.The Hematrix active patch is an innovative wound dressing made from polyurethane foam for severe injuries. It offers a large surface area to absorb blood flow and accelerate clotting. Infused with natural clotting factors, it triggers the clotting process upon contact with blood. Within minutes, the bleeding stops, and the patch can be safely removed. This prevents secondary bleeding and ensures unrestricted circulation while minimising the risk of hematoma.BIOVIIIx is also focused on understanding the impact of continuous blood loss, particularly its destructive effect on joints due to matrix oligomeric protein (MOC). Its research has significantly improved the lives of many affected by haemophilia, enhancing their ability to manage the coagulation cascade more effectively.Leading with Innovation and Sustainable HealthcareFor the past ten years, BIOVIIIx has invested a portion of its earnings before interest, taxes, depreciation and amortisation (EBITDA) into the research centre. It continues to dedicate its annual profits to developing new therapies for patients. Many of its new patented drugs are currently in phase one of development. The innovation philosophy extends beyond its products. BIOVIIIx is also committed to sustainability. A year and a half ago, it began efforts to reduce plastic use, which has earned it recognition as a green company. Creating a better world for future generations is fundamental to its vision. This dedication to compassionate, effective healthcare sets a new industry standard, making BIOVIIIx a leader in progress for haemophilia patients worldwide.BIOVIIIx's focus on scientific research, comprehensive support systems and global partnerships underscores its broader mission to provide effective healthcare. It is now poised to expand its business units and make more strategic investments in exploring novel molecules, aiming to reach new horizons in the care realm for haemophilia and rare diseases. BIOVIIIx is grounded in ethical and human-centric values. Its decision-making process focuses on projects that directly benefit patients, often foregoing immediate financial gains. This patient-centric approach leads the company to go above and beyond standard practices
< Page 9 | Page 11 >